Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCytogenetic AnalysisHumansMultiple MyelomaProgression-Free SurvivalConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting Items